A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (NCT04302025)

🧪 Interventions in This Study

• Alectinib (DRUG)
• Entrectinib (DRUG)
• Vemurafenib (DRUG)
• Cobimetinib (DRUG)
• Pralsetinib (DRUG)
• Atezolizumab (DRUG)
• SBRT (DRUG)
• Chemotherapy (DRUG)
• Divarasib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (38 Sites)

Showing the first 25 of 38 sites.

• City of Hope Comprehensive Cancer Center — Duarte, California
• City of Hope - Orange County Lennar Foundation Cancer Center — Irvine, California
• USC Norris Cancer Center — Los Angeles, California
• Cedars-Sinai Medical Center — Los Angeles, California
• University of California Los Angeles - Jonsson Comprehensive Cancer Center — Los Angeles, California
• The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange — Orange, California
• UC Davis Comprehensive Cancer Center — Sacramento, California
• UCSF Helen Diller Family CCC — San Francisco, California
• University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) — Aurora, Colorado
• Yale Cancer Center — New Haven, Connecticut
• MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) — Washington D.C., District of Columbia
• Moffitt Cancer Center — Tampa, Florida
• Northwestern University — Chicago, Illinois
• Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
• Northwestern Medicine Cancer Center Delnor — Geneva, Illinois
• Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
• Boston Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center — Farmington Hills, Michigan
• Mayo Clinic — Rochester, Minnesota
• Ellis Fischel Cancer Center — Columbia, Missouri
• Siteman Cancer Center - Washington University Medical Campus — St Louis, Missouri
• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
• Laura and ISAAC Perlmutter Cancer Center at NYU Langone. — New York, New York

📞 Contact the Study Coordinator

Phone: (888) 662-6728

Email: global-roche-genentech-trials@gene.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-small Cell Lung Cancer

• Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
• Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona

Explore by condition: All Non-small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.